Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand

Biochemical and Biophysical Research Communications

Volumn 354, Issue 2, 2007, Pages 447-452

  Shinmyouzu, Kouhei ^a   Takahashi, Tetsu ^a   Ariyoshi, Wataru ^a   Ichimiya, Hisashi ^a   Kanzaki, Shin ^a   Nishihara, Tatsuji ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Dermatan sulfate; Glycosaminoglycan; Macrophage colony stimulating factor; Osteoclast; Quartz crystal microbalance technique; Receptor activator of NF B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; DERMATAN SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE MARROW CELL; BONE METABOLISM; CELL CULTURE; DOSE RESPONSE; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOBLOTTING; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BINDING, COMPETITIVE; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; DERMATAN SULFATE; FEMALE; GROWTH INHIBITORS; MICE; OSTEOCLASTS; PROTEIN BINDING; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

MAMMALIA;

EID: 33846512913     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.221     Document Type: Article

References (41)

1. Lindahl U. 'Heparin'-from anticoagulant drug into the new biology. Glycoconj. J. 17 (2000) 597-605
2. Sasisekharan R., and Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr. Opin. Chem. Biol. 4 (2000) 626-631
3. Casu B., and Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv. Carbohydr. Chem. Biochem. 57 (2001) 159-206
4. Shriver Z., Liu D., and Sasisekharan R. Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc. Med. 12 (2002) 71-77
5. Sasisekharan R., Ernst S., and Venkataraman G. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1 (1997) 45-54
6. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., and Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3 (1997) 866-871
7. Fry E.E., Lea S.M., Jackson T., Newman J.W., Ellard F.M., Blakemore W.E., Abu-Ghazaleh R., Samuel A., King A.M., and Stuart D.I. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18 (1999) 543-554
8. Shukla D., Liu J., Blaiklock P., Shworak N.W., Bai X., Esko J.D., Cohen G.H., Eisenberg R.J., Rosenberg R.D., and Spear P.G. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99 (1999) 13-22
9. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., and Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5 (1999) 803-809
10. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., and Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5 (1999) 793-802
11. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., and Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth metastasis. Proc. Natl. Acad. Sci. USA 99 (2002) 568-573
12. Walton K.J., Duncan J.M., Deschamps P., and Shaughnessy S.G. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 100 (2002) 2530-2536
13. Bi Y., Stuelten C.H., Kilts T., Wadhwa S., Iozzo R.V., Robey P.G., Chen X.D., and Young M.F. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J. Biol. Chem. 280 (2005) 30481-30489
14. Bi Y., Nielsen K.L., Kilts T.M., Yoon A., M A.K., Wimer H.F., Greenfield E.M., Heegaard A.M., and Young M.F. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone 38 (2006) 778-786
15. Waddington R.J., Roberts H.C., Sugars R.V., and Schonherr E. Differential roles for small leucine-rich proteoglycans in bone formation. Eur. Cell Mater. 6 (2003) 12-21
16. Detamore M.S., Orfanos J.G., Almarza A.J., French M.M., Wong M.E., and Athanasiou K.A. Quantitative analysis and comparative regional investigation of the extracellular matrix of the porcine temporomandibular joint disc. Matrix Biol. 24 (2005) 45-57
17. Misinzo G., Delputte P.L., Meerts P., Lefebvre D.J., and Nauwynck H.J. Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J. Virol. 80 (2006) 3487-3494
18. Srinoulprasert Y., Kongtawelert P., and Chaiyaroj S.C. Chondroitin sulfate B and heparin mediate adhesion of Penicillium marneffei conidia to host extracellular matrices. Microb. Pathog. 40 (2006) 126-132
19. Kawashima H., Hirose M., Hirose J., Nagakubo D., Plaas A.H., and Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to l-selectin, P-selectin, and CD44. J. Biol. Chem. 275 (2000) 35448-35456
20. Kawashima H., Atarashi K., Hirose M., Hirose J., Yamada S., Sugahara K., and Miyasaka M. Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with l- and P-selectin and chemokines. J. Biol. Chem. 277 (2002) 12921-12930
21. Mitsunaga C., Mikami T., Mizumoto S., Fukuda J., and Sugahara K. Chondroitin sulfate/dermatan sulfate hybrid chains in the development of cerebellum. Spatiotemporal regulation of the expression of critical disulfated disaccharides by specific sulfotransferases. J. Biol. Chem. 281 (2006) 18942-18952
22. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., and Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96 (1999) 3540-3545
23. Theoleyre S., Kwan Tat S., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., Fortun Y., Padrines M., Redini F., and Heymann D. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem. Biophys. Res. Commun. 347 (2006) 460-467
24. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
25. Gange C.T., Quinn J.M., Zhou H., Kartsogiannis V., Gillespie M.T., and Ng K.W. Characterization of sugar binding by osteoclast inhibitory lectin. J. Biol. Chem. 279 (2004) 29043-29049
26. Amara A., Lorthioir O., Valenzuela A., Magerus A., Thelen M., Montes M., Virelizier J.L., Delepierre M., Baleux F., Lortat-Jacob H., and Arenzana-Seisdedos F. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J. Biol. Chem. 274 (1999) 23916-23925
27. Martin L., Blanpain C., Garnier P., Wittamer V., Parmentier M., and Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40 (2001) 6303-6318
28. Stringer S.E., Forster M.J., Mulloy B., Bishop C.R., Graham G.J., and Gallagher J.T. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. Blood 100 (2002) 1543-1550
29. Goger B., Halden Y., Rek A., Mosl R., Pye D., Gallagher J., and Kungl A.J. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 41 (2002) 1640-1646
30. Robinson C.J., Harmer N.J., Goodger S.J., Blundell T.L., and Gallagher J.T. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J. Biol. Chem. 280 (2005) 42274-42282
31. Takada T., Katagiri T., Ifuku M., Morimura N., Kobayashi M., Hasegawa K., Ogamo A., and Kamijo R. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J. Biol. Chem. 278 (2003) 43229-43235
32. Ariyoshi W., Takahashi T., Kanno T., Ichimiya H., Takano H., Koseki T., and Nishihara T. Mechanisms involved in enhancement of osteoclast formation and function by low molecular weight hyaluronic acid. J. Biol. Chem. 280 (2005) 18967-18972
33. Inoue A., Sasaki N., Kakudo K., Kamada A., Ikeo T., Mushimoto K., and Morita S. Detection of proteoglycans in human mandibular condylar cartilage. Jpn. J. Oral Maxillofac. Surg. 50 (2004) 57-63
34. Nishida E., and Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18 (1993) 128-131
35. Avruch J., Zhang X.F., and Kyriakis J.M. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem. Sci. 19 (1994) 279-283
36. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem. Sci. 19 (1994) 470-473
37. Iwasaki S., Hattori A., Sato M., Tsujimoto M., and Kohno M. Characterization of the bone morphogenetic protein-2 as a neurotrophic factor. Induction of neuronal differentiation of PC12 cells in the absence of mitogen-activated protein kinase activation. J. Biol. Chem. 271 (1996) 17360-17365
38. Cobb M.H., and Goldsmith E.J. How MAP kinases are regulated. J. Biol. Chem. 270 (1995) 14843-14846
39. Iwasaki S., Iguchi M., Watanabe K., Hoshino R., Tsujimoto M., and Kohno M. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem. 274 (1999) 26503-26510
40. Schwenger P., Alpert D., Skolnik E.Y., and Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol. Cell. Biol. 18 (1998) 78-84
41. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275 (2000) 31155-31161